Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study

Van Cutsem, E.; Boni, C.; Tabernero, J.; Massuti, B.; Middleton, G.; Dane, FAYSAL; Reichardt, P.; Pimentel, F.; Cohn, A.; Follana, P.; Clemens, M.; Zaniboni, A.; Moiseyenko, V.; Harrison, M.; Richards, D.; Prenen, H.; Pernot, S.; Ecstein-Fraisse, E.; Hitier, S.; Rougier, P.

doi:10.1093/annonc/mdu496

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study

Van Cutsem E., Boni C., Tabernero J., Massuti B., Middleton G., Dane F., ...More

ANNALS OF ONCOLOGY, vol.26, no.1, pp.149-156, 2015 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 26 Issue: 1
Publication Date: 2015
Doi Number: 10.1093/annonc/mdu496
Journal Name: ANNALS OF ONCOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.149-156
Keywords: antineoplastic agents, combined, platinum compounds, stomach neoplasms, taxoids, GASTROESOPHAGEAL JUNCTION, 1ST-LINE THERAPY, CISPLATIN, TRIAL, ADENOCARCINOMA, COMBINATION, EPIRUBICIN, CHEMOTHERAPY, DOXORUBICIN, MITOMYCIN
Marmara University Affiliated: Yes

Abstract

Docetaxel/cisplatin/infusional 5-fluorouracil (5-FU; DCF) is a standard chemotherapy regimen for patients with advanced gastric cancer (GC). This phase II study evaluated docetaxel/oxaliplatin (TE), docetaxel/oxaliplatin/5-FU (TEF), and docetaxel/oxaliplatin/capecitabine (TEX) in patients with advanced GC.